Who
Rabourn Amy Zaremba
Head of Fin. Quality Assurance
Company insider
Files Form 4 as: Head of Fin. Quality Assurance, Opus Genetics.
In numbers
- Trades disclosed
- 20
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $47K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Nov 2020
- Last trade
- 23 Apr 2026
- Last filed
- 27 Apr 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Apr 2026filed 27 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $8,5401,641 at $5.20 | filing |
| 23 Apr 2026filed 27 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $8,5331,641 at $5.20 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $15K2,816 at $5.25 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $15K2,816 at $5.25 | filing |
| 22 Jan 2026filed 26 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —86,500 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —86,500 at $0.00 | filing |
| 18 Jan 2026filed 21 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code F | $7,1193,390 at $2.10 | filing |
| 18 Jan 2026filed 21 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code F | $7,1193,390 at $2.10 | filing |
| 10 Jan 2026filed 13 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code F | $7,6243,950 at $1.93 | filing |
| 10 Jan 2026filed 13 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code F | $7,6243,950 at $1.93 | filing |
| 13 Mar 2025filed 17 Mar 2025 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,500 at $0.00 | filing |
| 13 Mar 2025filed 17 Mar 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —39,500 at $0.00 | filing |
| 4 Feb 2025filed 6 Feb 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code F | $9,3378,190 at $1.14 | filing |
| 18 Jan 2024filed 22 Jan 2024 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 18 Jan 2024filed 22 Jan 2024 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 10 Jan 2024filed 12 Jan 2024 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code F | $13K3,950 at $3.27 | filing |
| 10 Jan 2023filed 12 Jan 2023 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —69,912 at $0.00 | filing |
| 10 Jan 2023filed 12 Jan 2023 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —46,608 at $0.00 | filing |
| 28 Jan 2022filed 1 Feb 2022 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 11 Nov 2020filed 16 Nov 2020 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
News
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaIRD · manilatimes.net · 16 Oct 2026Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026IRD · manilatimes.net · 15 Oct 2026Opus Genetics to Present at the Chardan Annual Healthcare ConferenceIRD · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Rabourn Amy Zaremba; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.